Longevity and inequality. Who will really benefit from the life extension revolution?

AI may accelerate the development of longevity medicine, but the biggest question is not only whether people will live longer. It is also who will have access to that technology.

Longevity and inequality. Who will really benefit from the life extension revolution?

Table of contents

    Longevity is no longer just a dream of technologists

    Not long ago, radical life extension was associated mainly with transhumanism, futurism, and speculation. Today, the topic is beginning to move into a more practical debate: what happens to law, society, and health systems if AI-enabled technologies significantly extend healthy life?

    An article published in the Journal of Law, Medicine & Ethics is not another promise of biological immortality. It is an attempt to organize a question that may become one of the defining issues of the coming decades: should access to life-extending technologies be treated as a privilege, a premium service, a part of healthcare, or a potential human right?

    The authors argue that AI may accelerate research into biomarkers of aging, drugs targeting biological aging processes, and more personalized prevention. At the same time, they warn that without the right safeguards, the same technology may deepen existing inequalities.

    The key question is therefore not only: “will people live longer?”. It is rather: who will be able to live longer, healthier lives — and on what terms?

    Publication details

    This is not a clinical trial or a patient study, but a legal and ethical analysis of the implications of AI in the field of longevity. The authors examine technological development through the lens of international law, human rights, bioethics, and sustainable development.

    • Publication title: AI’s Promise of Healthy Longevity: Exploring the Implications of Extended Lifespans Under International Law.
    • Authors: Jon Truby and Indira Dewi Kantiana.
    • Affiliations: Centre for International Law, National University of Singapore, and Saw Swee Hock School of Public Health, National University of Singapore.
    • Online publication date: April 24, 2026.
    • Journal: Journal of Law, Medicine & Ethics, Cambridge University Press.
    • Publication type: independent article, legal and ethical analysis.
    • DOI: 10.1017/jme.2026.10262.
    • Full text: Cambridge Core.
    • License: open access article under the Creative Commons Attribution license.
    • Conflicts of interest: the authors declare no disclosures.
    • Use of AI in the writing process: the authors state that ChatGPT was used to improve the readability and language of the manuscript, while they retained responsibility for the content after review and editing.

    This publication does not provide new biological data on aging. Its value lies elsewhere: it shows that longevity medicine cannot be analyzed only through biomarkers, drugs, and algorithms.

    The risk of a new divide: the long-lived and the left behind

    The authors point out that current differences in life expectancy are already substantial. High-income countries often have life expectancies above 80 years, while in many low- and middle-income countries, especially in Sub-Saharan Africa, life expectancy can be much lower. If longevity technologies first reach the richest countries and wealthiest social groups, they may not reduce those differences, but lock them in and expand them.

    This matters because AI does not develop in a vacuum. Models, data, infrastructure, capital, and access to advanced healthcare are concentrated in selected parts of the world. This means that the longevity revolution may begin from an unequal starting point.

    The most concerning scenario looks like this:

    • The wealthiest populations gain access to personalized prevention, early diagnostics, and therapies that delay age-related diseases. In practice, this would mean not only more years of life, but more years of function, work, independence, and social influence.
    • Poorer populations continue to face preventable diseases, weak prevention, and limited access to basic healthcare. In this context, a technology meant to improve health could become another mechanism of economic advantage.
    • Differences in healthy lifespan may translate into differences in wealth, education, work, and social position. Longer healthy life gives people more time to accumulate capital, build careers, and benefit from social systems, which may reinforce existing inequalities.
    • There is a risk of a “longevity divide” between those who benefit from longer health and those who remain stuck in the old model of aging. This would not be only a medical inequality, but a deep civilizational inequality.

    That is why the question of longevity is not only about medicine. It is also about distributive justice, public policy, and whether future technologies will be treated as a common good or as a luxury product.

    Could there be a right to longer life?

    The most provocative part of the article concerns whether international law already contains the seeds of a right to longevity. The authors do not claim that such a right already exists explicitly. They show, however, that it can be considered through existing rights: the right to health, the right to life, and the right to enjoy the benefits of scientific progress.

    In practice, this creates tension between two ways of thinking. The first says that if a technology can prevent disease and premature death, states should gradually expand access to it. The second says that extending life beyond the traditional boundaries of healthcare may be something different from treating disease and does not automatically belong within the catalogue of basic services.

    This distinction matters enormously. If longevity interventions are recognized as part of the right to health, the pressure for their fair distribution will be much stronger. If they remain premium products, they will be governed mainly by market logic.

    The authors point to several questions that are likely to return more often:

    • Can aging be treated as a condition requiring intervention, or should it be seen as a natural part of life? The answer will shape whether technologies that slow aging are viewed as treatment, prevention, or human enhancement.
    • Should effective longevity interventions become public goods, similar to vaccines during health crises? If their impact on population health becomes large, it will be difficult to maintain the narrative that they are purely private luxuries.
    • How should states balance expensive technologies against basic health needs? Excessive funding for elite interventions may come at the expense of actions that save more lives here and now.
    • Can the right to long life ever be absolute? The authors suggest a more limited version: access to technology may be an important part of the right to health, but it must be constrained by safety, resources, fairness, and social responsibility.

    This shifts the debate from “do we want to live to 120?” to “how do we design a system in which longer life does not become a privilege for a few?”.

    The right to science means the right to share in its benefits

    The article strongly emphasizes the right to enjoy the benefits of scientific progress. This is especially important in the context of AI, because the effectiveness of algorithms depends on the data on which they are trained. If the data come mainly from wealthy countries, specific ethnic groups, younger populations, or better-studied patients, the technology may work less effectively for people outside those groups.

    In longevity, this has an additional dimension. Paradoxically, older adults may be one of the main target groups for healthy longevity technologies, while at the same time being underrepresented in the data, design, and testing of AI systems.

    That is why the right to science should not mean only passive access to finished therapies. It should also include participation in technology creation, fair data, education, and a real ability to influence how innovations are deployed.

    In practice, responsible development requires several conditions:

    • Datasets should be more representative of different populations, ages, sexes, regions, and social conditions. Without this, AI may reinforce errors and biases already embedded in healthcare systems.
    • Older adults should be included not only as recipients of technology, but also as participants in the design process. This reduces the risk of solutions that are technically impressive but poorly matched to real user needs.
    • States and companies should conduct human rights impact assessments of these technologies. This is especially important for privacy, discrimination, economic accessibility, and the risk of exclusion from the system.
    • The benefits of scientific breakthroughs should be shared more widely than only within the most profitable markets. If longevity is to become part of public health, it cannot be designed only for the wealthiest consumers.

    This is one of the most important conclusions of the article: AI in longevity will not be neutral if it is built on unrepresentative data and deployed in unequal systems.

    Longer life must have environmental and social limits

    The authors do not reduce the issue to the idea that “more life is always better.” They point out that longevity must also be analyzed in the context of sustainable development, climate, resources, bioethics, and responsibility toward future generations.

    This is an important counterweight to techno-optimistic narratives. Extending life may increase wellbeing, productivity, and time spent in health. But if it is pursued without reflection on resources, emissions, pension systems, long-term care, and intergenerational relations, it may create new tensions.

    The authors suggest that any future right to longevity — if such a right emerges — cannot mean an unconditional right to every technology. It must operate within broader safeguards.

    The most important limits are:

    • Biological and clinical safety. Interventions that affect aging processes, genes, cells, or the immune system must be evaluated not only for their promises, but also for long-term risks.
    • Intergenerational justice. Longer life for current generations should not come at the expense of future generations’ wellbeing, public resources, or social stability.
    • Environmental sustainability. AI, data centers, medical devices, wearables, and digital infrastructure all have their own energy and material footprint, which cannot be ignored.
    • Protection against new forms of exclusion. If access to longevity depends on place of birth, wealth, data quality, or the strength of a healthcare system, technology may become a tool of health segregation.

    In this sense, longevity is not only a biological project. It is a social project that requires asking: how can healthy life be extended without deepening inequality and without shifting the costs onto others?

    The most important takeaway

    The article does not say that AI will definitely allow people to live to 120. It also does not say that a right to longevity already exists in a clear and complete form. Its main message is more subtle: if longevity technologies become effective, the world will not be able to treat them only as private innovations for those who can pay.

    The key takeaway is this: longevity may become one of the major tests of justice in the 21st century. Not because everyone will have a right to immortality, but because access to additional years of health may become one of the most powerful forms of social advantage.

    For people interested in longevity, this is an important warning. The conversation about aging cannot end with supplements, biomarkers, interventions, and technology. It must also include access, data, costs, regulation, and responsibility.

    If AI really accelerates longevity medicine, the central question will not only be “can we extend life?”. It will be: can we do it in a way that prevents longer healthy life from becoming a luxury for a narrow group of people?

    Sources